Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Hematology Department Soroka UMC / Heanatology Department

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of the Hematology Department at Soroka UMC, detailing its management structure, collaborations, and patient studies. It highlights ongoing research initiatives, including the TakeAim studies for various hematological conditions. Additionally, the article outlines the company's pipeline of drug candidates and resources available for investors and patients.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 8 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by the Hematology Department?

The Hematology Department sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is the focus of the TakeAim studies?

The TakeAim studies focus on various hematological conditions, including lymphoma and leukemia.

What drugs are included in the pipeline overview?

The pipeline includes drugs like Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

What resources are available for investors?

Resources for investors include press releases, financial information, and annual reports.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Soroka UMC Hematology TakeAim studies clinical trials
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →